A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults with Head and Neck Cancer
Study of ADU-S100 and Pembrolizumab in Head and Neck Cancer
Sponsor: Aduro Biotech, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS5154
U.S. Govt. ID: NCT03937141
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to study ADU-S100 and pembrolizumab in patients with recurrent or metastatic head and neck squamous cell cancer (HNSCC). This study aims to evaluate how safe and effective this drug combination is at treating your cancer. These drugs are thought to work by interacting with your immune system to in order to more effectively fight your tumors.
This study is closed
Investigator
Matthen Mathew, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with recurrent or metastatic head and neck sqamous cell cancer (HNSCC)? Yes No
Are you willing to have tumor biopsies completed? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE